A new article was published in Frontiers in Pharmacology

Sokolov V, Yakovleva T, Penland RC, Boulton DW and Tang W (2023) Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model. Front. Pharmacol. 14:1229255. doi: 10.3389/fphar.2023.1229255

In this work, a semi-mechanistic exposure-response model was developed to deconvolute and reconstruct dapagliflozin-HbA1c dose-response relationship in type 1 diabetes by accounting for the drug’s action on both daily insulin dose and plasma glucose on a subject-level.